Ascendis Pharma As Stock Investor Sentiment

ASND Stock  USD 152.61  1.08  0.71%   
About 57% of all Ascendis Pharma's shareholders are looking to take a long position. The analysis of the overall investor sentiment regarding Ascendis Pharma AS suggests that some traders are interested. The current market sentiment, together with Ascendis Pharma's historical and current headlines, can help investors time the market. In addition, many technical investors use Ascendis Pharma AS stock news signals to limit their universe of possible portfolio assets.

Comfort Level 57

 Interested

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Ascendis Pharma's input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Ascendis Pharma AS.

Ascendis Historical Sentiment

Although Ascendis Pharma's investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Ascendis, such as negative comments on social media and news outlets, may cause fear in the market and push Ascendis Pharma's investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Ascendis.
  

Ascendis Pharma Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Ascendis Pharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Ascendis Pharma AS Historical Investor Sentiment

Investor biases related to Ascendis Pharma's public news can be used to forecast risks associated with an investment in Ascendis. The trend in average sentiment can be used to explain how an investor holding Ascendis can time the market purely based on public headlines and social activities around Ascendis Pharma AS. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Ascendis Pharma's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Ascendis Pharma and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Ascendis Pharma news discussions. The higher the estimate score, the more favorable the investor's outlook on Ascendis Pharma.

Ascendis Pharma Maximum Pain Price Across April 17th 2025 Option Contracts

Ascendis Pharma's options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Ascendis Pharma close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Ascendis Pharma's options.
a day ago at thelincolnianonline.com         
Ascendis Pharma AS Shares Sold by Handelsbanken Fonder AB
news
2 days ago at gurufocus.com         
Ascendis Pharma AS to Participate in TD Cowen 45th Annual Health Care Conference
Gurufocus Stories at Macroaxis
3 days ago at finance.yahoo.com         
Ascendis Pharma to Participate in theTD Cowen 45th Annual Health Care Conference
Yahoo News
3 days ago at gurufocus.com         
Ascendis Pharma to Participate in theTD Cowen 45th Annual Healt
Gurufocus Stories at Macroaxis
six days ago at benzinga.com         
Why Is BioMarin Stock Trading Higher On Thursday?
benzinga news
six days ago at finance.yahoo.com         
FIRST AND ONLY TREATMENT FOR CHRONIC HYPOPARATHYROIDISM APPROVED IN AUSTRALIA
Yahoo News
over a week ago at thelincolnianonline.com         
Q1 EPS Forecast for Ascendis Pharma AS Decreased by Analyst
news
over a week ago at finance.yahoo.com         
Exploring High Growth Tech Stocks Including Lime Technologies And Two Others
Yahoo News
over a week ago at thelincolnianonline.com         
Rice Hall James Associates LLC Has 22.56 Million Stock Holdings in Ascendis Pharma AS
news
over a week ago at finance.yahoo.com         
High Growth Tech Stocks And 2 More High Potential Picks
Yahoo News
over a week ago at gurufocus.com         
RA CAPITAL MANAGEMENT, L.P. Reduces Stake in Recursion Pharmaceuticals Inc
Gurufocus Stories at Macroaxis
over a week ago at simplywall.st         
Ascendis Pharma AS Yearly Results Heres What Analysts Are Forecasting For This Year
Simply Wall St News at Macroaxis
over a week ago at finance.yahoo.com         
Ascendis Pharma AS Just Reported Annual Earnings Have Analysts Changed Their Mind On The Stock?
Yahoo News
over a week ago at gurufocus.com         
RA CAPITAL MANAGEMENT, L.P. Reduces Stake in Day One Biopharmaceuticals Inc
Gurufocus Stories at Macroaxis
over a week ago at gurufocus.com         
JANUS HENDERSON GROUP PLC Expands Stake in Ascendis Pharma AS
Gurufocus Stories at Macroaxis
Far too much social signal, news, headlines, and media speculation about Ascendis Pharma that are available to investors today. That information is available publicly through Ascendis media outlets and privately through word of mouth or via Ascendis internal channels. However, regardless of the origin, that massive amount of Ascendis data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Ascendis Pharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Ascendis Pharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Ascendis Pharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Ascendis Pharma alpha.

Ascendis Pharma Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
YORVIPATH Now Commercially Available in the United States for the Treatment of Hypoparathyroidism in Adults
12/19/2024
2
Heres How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years - Benzinga
01/23/2025
3
Ascendis Pharma AS Posts Earnings Results, Beats Estimates By 0.64 EPS
02/12/2025
4
Ascendis Pharma AS Q4 2024 Earnings Call Transcript
02/13/2025
5
Ascendis Pharma AS Q4 2024 Earnings Call Highlights Strategic Growth and Market ...
02/14/2025
6
Q1 EPS Forecast for Ascendis Pharma AS Decreased by Analyst
02/19/2025
7
Ascendis Pharma to Participate in theTD Cowen 45th Annual Healt
02/24/2025
8
Ascendis Pharma AS Shares Sold by Handelsbanken Fonder AB
02/26/2025

Complementary Tools for Ascendis Stock analysis

When running Ascendis Pharma's price analysis, check to measure Ascendis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ascendis Pharma is operating at the current time. Most of Ascendis Pharma's value examination focuses on studying past and present price action to predict the probability of Ascendis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ascendis Pharma's price. Additionally, you may evaluate how the addition of Ascendis Pharma to your portfolios can decrease your overall portfolio volatility.
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing